Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness

Simply Wall St.02-16

AdvertisementWhy Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611200811?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-16 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611200811","market":"nz","top_or_hot":-1,"title":"Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-16 00:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","article_id":"2611200811","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611200811","pubTimestamp":1771172947,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Suzhou Ribo Life Science Is Drawing Investor Attention\nSuzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline.\nSee our latest analysis for Suzhou Ribo Life Science.\nThe latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"苏州日博生命科学（SEHK：6938）近期股价疲软后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":0.9},"content_text":"AdvertisementWhy Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline. See our latest analysis for Suzhou Ribo Life Science. The latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a year to date share price return of a 14.68% decline. Taken together, these figures point to fading momentum over recent months as investors reassess the risk and timing of Suzhou Ribo Life Science’s drug development pipeline. If you are thinking about other ways to position around healthcare and biotech trends, it could be worth scanning our list of 107 healthcare AI stocks to see what else stands out. With Suzhou Ribo Life Science posting a HK$220.731 million loss on HK$180.135 million of revenue and a weak year to date share price, is the recent pullback a potential entry point, or is the market already factoring in future growth? Preferred Multiple of Price-to-Book: Is it justified? For Suzhou Ribo Life Science, the usual shortcut of comparing valuation through a P/B multiple quickly runs into a red flag, because the company currently has negative equity and a Price-to-Book Ratio of -180.7x. P/B typically compares a company’s market value to its net assets, which can help you judge how much investors are paying relative to the balance sheet. When equity is negative, that calculation becomes less meaningful for comparison, because the denominator is below zero and small shifts in equity can produce very large or distorted ratios. Here, the reported P/B of -180.7x stands far away from both the peer group average of 30.4x and the Hong Kong biotechs industry average of 4.4x. That gap is driven by the capital structure and accumulated losses rather than a straightforward premium or discount, so it gives limited help when you try to frame the current HK$70.05 share price against fundamentals. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of -180.7x (ABOUT RIGHT TO TREAT WITH CAUTION) However, you still need to weigh risks such as ongoing losses of HK$220.731 million and the uncertainty around multiple clinical and preclinical trial outcomes. Find out about the key risks to this Suzhou Ribo Life Science narrative.  Build Your Own Suzhou Ribo Life Science Narrative If this take does not fully line up with your view, or you would rather work through the numbers yourself, you can build a custom thesis for Suzhou Ribo Life Science in just a few minutes, starting with Do it your way. A great starting point for your Suzhou Ribo Life Science research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you only stick with stocks you already know, you could miss opportunities that better fit your goals, so take a moment to scan a few targeted shortlists.  Spot potential turnaround stories with 227 elite penny stocks with strong financials that already show stronger financial footing than many expect from low priced names. Zero in on quality at a price that could appeal to value focused investors by checking our 229 high quality undervalued stocks. Prioritise staying power by reviewing companies in the 321 resilient stocks with low risk scores that pair resilience scores with fundamentals you can scrutinise in more detail.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611200811","isCrawlerRequest":true}